Back to GILD Stock Lookup

Gilead Sciences (GILD) – Reports

Oct 4, 2022 03:36 PM Today's Most Important Upgrades
Oct 4, 2022 09:06 AM Rivian, Poshmark, Tesla Rise Premarket; Kalvista Pharmceuticals Falls
Oct 4, 2022 07:31 AM JPMorgan Upgrades Gilead (GILD), Says Emerging Oncology Franchise is Not Reflected in Valuation
Oct 4, 2022 06:32 AM UPDATE: JPMorgan Upgrades Gilead Sciences (GILD) to Overweight; 'Becoming Less Controversial with Increased Visibility'
Oct 3, 2022 09:01 AM Gilead Sciences' (GILD) Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
Sep 20, 2022 04:31 PM Gilead Sciences (GILD) Completes Acquisition of MiroBio
Sep 16, 2022 07:02 AM Gilead Sciences (GILD) Announces Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and HGBL
Sep 16, 2022 06:39 AM Gilead Sciences (GILD) Reports Positive CHMP Opinion for Treatment of Pediatric Patients with Veklury
Sep 16, 2022 05:50 AM Gilead Sciences (GILD) Announces WHO's Expanded Recommendation for Veklury for Patients With Severe COVID-19
Sep 14, 2022 09:52 AM Gilead Sciences (GILD) PT Raised to $76 at Truist Securities as Generic Patent Challenges Settled
Sep 13, 2022 12:01 PM Gilead Sciences (GILD) PT Raised to $83 at RBC Capital, 'HIV IP Settlement Should Add $22B Aggregate Revs'
Sep 13, 2022 06:35 AM Gilead Sciences (GILD) PT Raised to $74 at Wells Fargo
Sep 12, 2022 03:48 PM Gilead Sciences (GILD) Settlement to Meaningfully Extend Exclusivity of HIV Agents
Sep 12, 2022 09:38 AM Mizuho Securities on Gilead Sciences (GILD) 8-K TAF Patent Resolution
Sep 12, 2022 08:42 AM RBC Capital on Gilead Sciences (GILD): 'We view this as a key positive for the HIV franchise'
Sep 12, 2022 08:39 AM Gilead Sciences (GILD) enters agreements to resolve litigation and patent challenges associated with Descovy, Vemlidy, and Odefsey
Sep 8, 2022 04:20 AM Gilead Sciences (GILD) Might Trade Higher Today Says RBC
Aug 31, 2022 08:42 AM Jefferies Positive on Gilead (GILD) Into ESMO, Says Stock Cheap with ~5% Dividend Yield
Aug 29, 2022 08:32 AM Gilead Sciences (GILD) Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types
Aug 22, 2022 05:42 AM Gilead Sciences (GILD) Granted Approval of Sunlenca in EU
Aug 16, 2022 05:55 AM Gilead Sciences (GILD) Acquires Remaining Worldwide Rights of Trodelvy
Aug 15, 2022 09:43 AM Gilead Sciences (GILD) PT Raised to $83 at RBC Capital
Aug 15, 2022 08:33 AM Gilead Sciences (GILD) Announces Trodelvy Significantly Improves OS in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
Aug 8, 2022 07:10 AM Gilead Sciences (GILD) PT Lowered to $71 at Truist Securities
Aug 4, 2022 08:03 AM Gilead Sciences (GILD) Acquires MiroBio
Aug 3, 2022 06:54 AM Gilead Sciences (GILD) PT Raised to $81 at RBC Capital
Aug 3, 2022 05:55 AM "Yet to See True Next Leg of Growth" - BMO Capital Keeps Gilead Sciences (GILD) at Market Perform
Aug 2, 2022 04:31 PM Gilead quarterly profit falls as COVID antiviral sales decrease
Aug 2, 2022 04:03 PM Gilead Sciences (GILD) Tops Q2 EPS by 6c, Offers Guidance
Aug 2, 2022 10:29 AM Gilead Sciences (GILD) August weekly option implied volatility into quarter results
Aug 1, 2022 04:36 PM JPMorgan Assumes Gilead Sciences (GILD) at Neutral
Jul 26, 2022 06:11 AM Gilead Sciences (GILD) PT Raised to $71 at Piper Sandler
Jul 22, 2022 09:42 AM Gilead Sciences (GILD) Announces Kite’s CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia
Jul 22, 2022 07:06 AM Gilead Sciences (GILD) Receives Positive CHMP Opinion Recommending Veklury Receive Full Marketing Authorization
Jul 19, 2022 03:57 PM EU signs COVID-19 drug procurement deal with Gilead
Jul 19, 2022 09:00 AM Gilead Sciences (GILD) Enters Procurement Agreement with the European Commission for Veklury
Jul 19, 2022 07:21 AM EU signs COVID-19 drug procurement deal with Gilead - Reuters
Jul 12, 2022 04:27 PM Cantor Fitzgerald Starts Gilead Sciences (GILD) at Neutral
Jun 28, 2022 06:02 AM Gilead Sciences (GILD) Granted EU Approval for Yescarta for Treatment of Relapsed or Refractory Follicular Lymphoma
Jun 27, 2022 04:30 PM Gilead Sciences (GILD) Resubmits NDA to FDA for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
Jun 24, 2022 08:00 AM Gilead Sciences (GILD) Announces Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Jun 23, 2022 08:31 AM Gilead Sciences (GILD) Announces Treatment With Hepcludex Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Jun 6, 2022 09:20 AM Morgan Stanley Sees Risks to Gilead Sciences (GILD) Trodelvy Accelerated Approval
Jun 6, 2022 09:00 AM Gilead Sciences (GILD) Reports Final Data From Phase 3 ASCENT Study Showing Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Jun 6, 2022 06:30 AM BMO Capital Reiterates Market Perform Rating on Gilead Sciences (GILD)
Jun 6, 2022 05:51 AM Gilead Sciences (GILD) Reports Tecartus Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up
Jun 4, 2022 01:38 PM Gilead Sciences (GILD) Reports Trodelvy Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 3, 2022 04:00 PM Gilead Sciences's (GILD) Kite Announces Yescarta CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
May 23, 2022 03:43 AM UPDATE: SVB Leerink Assumes Gilead Sciences (GILD) at Market Perform, 'Inexpensive Valuation, but Pipeline Needs Validation'
May 17, 2022 04:02 AM Gilead Sciences (GILD) PT Lowered to $69 at Piper Sandler

Back to GILD Stock Lookup